News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Clinuvel Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
First patient with rare skin disorder receives Clinuvel drug
News
Top 50 ASX small caps of 2018: Where are they now?
Health & Biotech
Large caps deny they’re being outgunned by smaller peers in health R&D
Health & Biotech
Dr Boreham’s Crucible: Why Invex has all the right ingredients to possibly become a takeover target
Health & Biotech
Clinuvel ready to sell its skin disorder treatment in the US; next up — a treatment that might have cured Michael Jackson
News
The traps and the opportunities: How to play equity markets in a global pandemic
Health & Biotech
Health: Wheeler dealer Probiotec spending money to make money
Health & Biotech
Dr Boreham’s Crucible: Why CSL is the poster child for most junior drug developers
Health & Biotech
Health: New US guidelines on breast cancer may help this ASX biotech
Health & Biotech
Health might be another overnight success in 2020
Health & Biotech
Health: PainChek reveals exactly how much its grown in 2019; and says there’s more to come next year
Health & Biotech
The health sector has been the ASX’s top performer in 2019, but could a recession stop it in its tracks?
Health & Biotech
Here’s what policymakers must do keep ASX life science companies from going overseas
Health & Biotech
Dr Boreham’s Crucible: Can Phylogica finally make magic happen after nearly 15 years of trying?
Health & Biotech
Biotech investors get ready to catch the next wave
Health & Biotech
Dr Boreham’s Crucible: the story of Clinuvel, an Australian triumph
Health & Biotech